Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Eftilagimod alpha + Paclitaxel |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Eftilagimod alpha | IMP321|LAG-31g|Immufact | Eftilagimod alpha (IMP321) is a recombinant soluble LAG3 protein, which binds to MHC Class II molecules, resulting in increased dendritic cell maturation and potentially leading to enhanced anti-tumor immune response (PMID: 16621192, PMID: 17785860, PMID: 20653948, PMID: 30977393). | ||
Paclitaxel | Taxol | 7-Epipaclitaxel | Antimicrotubule Agent 14 BCL2 Family Inhibitor 6 | Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05747794 | Phase II | Paclitaxel Eftilagimod alpha + Paclitaxel | Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy (AIPAC-003) | Recruiting | USA | ESP | BEL | 2 |